Kinetik von HBs-Antigen-Spiegeln bei Patienten mit chronischer Hepatitis B während 4 Jahren Therapie mit Tenofovir oder Adefovir
F van Boemmel, B Fülöp, A Brodzinski, FJ Bock, B Schlosser, M Biermer, V Weich, K Hensel-Wiegel, E Schott, B Wiedenmann, T Berg · Zeitschrift für Gastroenterologie · 2010 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: The ultimate endpoint in antiviral treatment of chronic HBV infections is the clearance of HBsAg. As recently shown, during 2 years of treatment with the nucleotide analogue tenofovir (TDF) the loss of HBsAg can be predicted by baseline and on- treatment parameters. We investigated serum HBsAg levels in patients treated with either TDF or adefovir (ADV) up to 4 years. Methods: 116 patients (77 male, 81 HBeAg positive, mean HBV DNA 7.1±2 [range, 4–9.1] copies/mL, HBV genotypes A, B, C, D, E in 41, 5, 11, 55, 2 patients) with chronic HBV infection and treatment with either ADV 10mg (n=61) or TDF 300mg/day (n…
